Meridian Bioscience (VIVO) Misses Q1 EPS by 5c; Lowers Outlook, Cuts Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Meridian Bioscience Reports First Quarter 2017 Operating Results, Reduces Regular Cash Dividend, and Revises Fiscal 2017 Guidance Downward
January 25, 2017 7:30 AM ESTGENERAL HIGHLIGHTS
CINCINNATI, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
reported first quarter net revenues of $46.8 million, a decrease of 1% from the same period of the prior fiscal year; reported first quarter operating income of $10.1 million, a decrease of 26% from the same period of the prior fiscal year; reported first quarter net earnings of $6.3 million, or $0.15 per diluted share, decreases... More